目的：探讨分析肺癌原发灶及转移淋巴结肿瘤干细胞标记物CD133和CD44的表达情况。方法选择我院收治的40例肺癌患者作为观察对象，采用免疫组化染色检测CD133和CD44在患者的肿瘤原发灶以及转移淋巴结中的表达情况，观察分析肿瘤大小、淋巴结转移情况、细胞分化程度与其表达情况的关系。结果40例肺癌患者中，淋巴结转移25例，占62.5%（25/40）。CD133和CD44在淋巴结转移中的阳性表达率分别为92%（23/25）、72%（18/25）；CD133和CD44在原病灶中的阳性表达率分别为72.5%（29/40）、57.5%（23/40）；CD133和CD44阳性组与阴性组原发灶肿瘤大小之间的比较均无显著差异（P＞0.05）。结论肺癌原发灶及转移淋巴结中肿瘤干细胞标记物CD133和CD44的表达情况与肿瘤生物学有直接的关系，对患者的预后有直接的影响。%Objective To study the analysis of the primary tumors and lung cancer metastasis lymph node cancer stem cell marker CD133 and the expression of CD44. Methods 40 cases of our hospital patients with lung cancer as research object, using immunohisto chemical staining detection CD133 and CD44 in patients with primary tumors and tumor metastasis lymph nodes in the expression, analyze the tumor size, lymph node metastasis, the relationship between the degree of cell differentiation and its expression. Results 40 cases of lung cancer patients, lymph node metastasis 25 cases, 62.5%(25/40). CD133 and positive expression of CD44 in lymph node metastasis rate was 92% (23/25), 72% (18/25), CD44 and CD133 positive expression rate in the original lesions were 72.5%(29/40), 57.5%(23/40), CD44 and CD133 positive group and negative group comparison between primary focal tumor size had no signiifcant difference (P>0.05). Conclusion Lung cancer primary tumors and the metastasis lymph nodes in the cancer stem cell marker CD133 and the expression of CD44 and tumor biology has a direct relationship, has a direct inlfuence on the prognosis of patients.
展开▼
